John P. Greer
YOU?
Author Swipe
View article: A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma Open
Diffuse large B-cell lymphoma (DLBCL) is curable in about 2/3 of patients with R-CHOP immunochemotherapy. Risk stratification of DLBCL that employs the International Prognostic Index (IPI) is a robust predictive prognostic model, developed…
View article: Supplementary Methods from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Supplementary Methods from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Methods
View article: Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Conflict of Interest Form
View article: Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Conflict of Interest Form
View article: Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Conflict of Interest Form
View article: Data from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Data from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Targeting somatically activated oncogenes has revolutionized the treatment of non–small cell lung cancer (NSCLC). Mutations in the gene mesenchymal–epithelial transition (MET) near the exon 14 splice sites are recurrent in lung adenocarcin…
View article: Data from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Data from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Targeting somatically activated oncogenes has revolutionized the treatment of non–small cell lung cancer (NSCLC). Mutations in the gene mesenchymal–epithelial transition (MET) near the exon 14 splice sites are recurrent in lung adenocarcin…
View article: Supplementary Figure Legends from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Supplementary Figure Legends from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Figure Legends
View article: supplementary figures 1-5 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
supplementary figures 1-5 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Figure 1: A survey of MET mutations and expression across TCGA datasets from diverse cancer types. Supplementary figure 2, MET exon 14 status and trypsin assay Supplementary Figure 3 MET half-life assay results Supplementary …
View article: Supplementary Figure Legends from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Supplementary Figure Legends from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Figure Legends
View article: Supplementary Tables 1 and 2 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Supplementary Tables 1 and 2 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Tables 1 and 2
View article: Supplementary Methods from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Supplementary Methods from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Methods
View article: Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Conflict of Interest Form from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Conflict of Interest Form
View article: Supplementary Tables 1 and 2 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Supplementary Tables 1 and 2 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Tables 1 and 2
View article: supplementary figures 1-5 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
supplementary figures 1-5 from <i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma Open
Supplementary Figure 1: A survey of MET mutations and expression across TCGA datasets from diverse cancer types. Supplementary figure 2, MET exon 14 status and trypsin assay Supplementary Figure 3 MET half-life assay results Supplementary …
View article: 123 Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy
123 Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy Open
Background The primary target of T-cell responses to cancer cells are peptides derived from non-synonymous mutations presented by HLA. However, the large diversity of HLA alleles and restricted availability of clinical samples has limited …
View article: 320 Rapid identification of a TCR library targeting the HPV E6/E7 oncoproteins to enable multi-TCR T-cell therapies for patients with HPV16+ epithelial cancers
320 Rapid identification of a TCR library targeting the HPV E6/E7 oncoproteins to enable multi-TCR T-cell therapies for patients with HPV16+ epithelial cancers Open
Background In the United States, the HPV16 strain is responsible for nearly 60% of newly diagnosed HPV-driven cancers. HPV16 drives oncogenesis through persistent expression of the E6 and E7 oncoproteins.1 The viral antigens E6 and E7 are …
View article: <i>TG-Interacting Factor 1</i> expression quantitatively impacts survival in acute myeloid leukemia
<i>TG-Interacting Factor 1</i> expression quantitatively impacts survival in acute myeloid leukemia Open
Applying transcriptional profiling analysis to myeloblasts from 59 adult patients with acute myeloid leukemia (AML) treated at our institution, we found that expression of the three-amino acid loop extension (TALE) homeobox gene TG-Interac…
View article: Seven Decades of Chemotherapy Clinical Trials: A Pan-Cancer Social Network Analysis
Seven Decades of Chemotherapy Clinical Trials: A Pan-Cancer Social Network Analysis Open
Background Clinical trials establish the standard of care for cancer and other diseases. While social network analysis has been applied to basic sciences, the social component of clinical trial research is not well characterized. We examin…
View article: Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry Open
Background: Outcomes for patients with peripheral T-cell lymphoma (PTCL) who fail to achieve complete response (CR) or relapse after front-line therapy are poor with lack of prospective outcomes data. Objectives: COMPLETE is a prospective …
View article: Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience
Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience Open
Dosing regimens for antithymocyte globulin (ATG) and anti-CD52 antibody (alemtuzumab) for graft vs. host disease prophylaxis (GVHD) are empiric or weight-based, and do not account for individual patient factors. Recently, it has been shown…
View article: Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma
Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma Open
Primary central nervous system lymphoma (PCNSL) patients have a poorer prognosis than systemic lymphoma. Gain-of-function MYD88 c.794T > C (p. L265P) mutation and programed cell death-1 (PD-1) pathway alterations are potential targetable p…
View article: The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study
The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Open
Background The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T‐cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patient…
View article: Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass
Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass Open
Mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkin lymphoma predominantly affecting male individuals of advanced age. Approximately 1–9% of cases of lymphoma affecting the orbital and ocular adnexal regions are attributed to MCL…
View article: Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia
Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia Open
Background: Older patients with severe aplastic anemia (SAA) needing hematopoietic cell transplantation (HCT) typically require utilization of reduced intensity conditioning (RIC) regimens; however, use of RIC regimens in this population i…